Here’s what you should know.
Vizient awarded the designation because of the company’s D-Light C Photodynamic Diagnostic system. The system detects and manages non-muscle invasive bladder cancer.
Vizient’s designation defines products that “hospitals truly value.”
Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program said “Vizient’s member council agreed [diagnostic system] offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology designation.
More articles on gastroenterology/endoscopy:
Exact Sciences, Takeda Pharmaceuticals & more — 6 GI company key notes
GI leader to know: Dr. Deborah Blalock of Blalock GI Care
How investors reacted to Valeant’s $2.1B sell off: 4 key insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.